Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 07 04:00PM ET
23.19
Dollar change
-0.19
Percentage change
-0.81
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y- Shs Outstand Perf Week0.26%
SponsorAmplify Investments ETF Type Tagsequity Return% 3Y- Total Holdings30 Perf Month2.28%
Fund Family Bond Type Tagshealthcare Return% 5Y- AUM4.18M Perf Quarter-7.93%
IndexVettaFi Weight Loss Drug & Treatment Ind... Average Maturity Tagspharmaceutical Return% 10Y NAV% Perf Half Y-7.74%
Index Weighting Commodity Type Tags- Return% SI NAV/sh Perf Year-
Active/Passive Quant Type Tags- Flows% 1M0.00% 52W Range22.00 - 28.19 Perf YTD2.84%
Dividend TTM0.22 (0.95%) ESG Type Tags- Flows% 3M0.00% 52W High-17.75% Beta-
Dividend Ex-DateDec 30, 2024 Dividend Type Sector/Theme Flows% YTD0.00% 52W Low5.41% ATR (14)0.29
Expense0.59% Structure Type Region Flows% 1Y RSI (14)53.13 Volatility0.84% 0.74%
Option/ShortNo / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.79 Prev Close23.38
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume2.05K Price23.19
SMA201.70% SMA50-0.06% SMA200-8.48% Trades Volume1,612 Change-0.81%
Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists (glucagon-like peptide) seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.